Affiliation:
1. 1Government taluk hospital, Assistant surgeo, Chalakudy, Thrissur, Kerala
2. 2Department of Pharmacology, Sri Ramachandra Medical College and Research Institute
Abstract
Background: Benign prostatic hypertrophy (BPH) is a common entity among elderly men and is responsible for significant disability. Medical treatment for BPH has played a major role in improving the symptoms associated with bladder outlet obstruction. Recent guidelines recommend the combination of an alpha-1 blocker and a 5-ARI as first-line treatment of men with moderate-to-severe LUTS. There is limited study data to support which is the effective therapy for BPH/LUTS in a tertiary care hospital in India. Methods: A randomized, open labelled, double blind, active control parallel group study comparing the safety and efficacy of tamsulosin versus tamsulosin+finasteride in subjects with lower urinary tract symptoms secondary to benign prostatic hypertrophy. The subjects were randomized after obtaining written informed consent. The subjects were recruited from the patient population that was attending the Out-Patient department of Urology, Sri Ramachandra Medical College & Research Institute, Sri Ramachandra University. Results: A total sample of 60 subjects, 30 into each group was enrolled. In the tamsulosin group, according to IPSS score, 11 patients who had moderate symptoms (36.7%) became mild, and among 19 patients who had severe symptoms (63.3%), 12 patients became mild (40%) and 7 patients became moderate (23.3%) with a p value of 0.021 which is statistically significant. In the tamsulosin+ finasteride group, according to IPSS score, 10 patients who had moderate symptoms (33.3%) became mild, and among 20 patients who had severe symptoms (66.7%), 12 patients became mild (40%) and 8 patients became moderate (26.7%) with a p value of 0.020 which is statistically significant. When comparing between the two groups, 76.7% attained mild symptoms in group 1 and 73.3% patients attained mild symptoms in group 2 with a p value of 0.766 which is statistically not significant. Conclusion: To conclude tamsulosin 0.4mg is as effective as the combination therapy of tamsulosin 0.4mg and finasteride 5mg in the treatment of lower urinary tract symptoms secondary to Benign prostatic hypertrophy.
Publisher
Oriental Scientific Publishing Company
Reference21 articles.
1. 1. Deepak Sundaram, Ponnusamy Kasirajan Sankaran, Gunapriya Raghunath, S Vijayalakshmi, J Vijayakumar, Maria Francis Yuvaraj, Munnusamy Kumaresan, and Zareena begum. Correlation of Prostate Gland Size and Uroflowmetry in Patients with Lower Urinary Tract Symptoms; J Clin Diagn Res. 2017 May; 11(5): AC01–AC04.
2. 2. Kevin T McVary, Clinical Evaluation of Benign Prostatic Hyperplasia; Rev Urol. 2003; 5(Suppl 4): S3–S11.
3. 3. Herbert Lepor. Pathophysiology of Benign Prostatic Hyperplasia in the Aging Male Population; Rev Urol. 2005; 7(Suppl 4): S3–S12.
4. 4. Jason M. Hirshburg, Petra A. Kelsey, A. Therrien, A. Carlo Gavino, Jason S. Reichenberg, Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review. J Clin Aesthet Dermatol. 2016 Jul; 9(7): 56–62.
5. 5. Eric H. Kim, John A. Brockman, and Gerald L. Andriole; The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia; Asian J Urol. 2018 Jan; 5(1): 28–32.